(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
South Korea launches Earth-observation satellite on homegrown Nuri rocket - 2Building a Maintainable Closet: Individual Excursions in Moral Style
- 3Chemical leak in Oklahoma forces evacuations and leaves many ill
- 4The Tiny Channel Island With 65 Residents That Chefs And Foodies Go Out Of Their Way To Visit
- 5Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- Huge solar flare no threat to Artemis 2 astronaut launch to the moon, NASA says
- Most loved Occasion Dish: What Makes Your Merry Table?
- 'Spending more on gas than groceries:' Rising fuel prices drive more San Antonio families to the Food Bank amid Iran war
- NMG signs new graphite supply deal with Canadian Government
- Artemis 2 astronaut Victor Glover delivers inspiring Easter message on the way to the moon (video)
- \Step by step instructions to Pick the Best Material Organization for Your Home\
- 'Everyone in this prison has had family killed or shot'
- Overhaul Your Rest: Tips for a Serene Evening
- Malaysian broadcaster rejects altered graphic about electricity rate hike
